# US 8,785,601 B2 · T cell receptors and related materials and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,785,601 B2
- Document ID: US8785601B2
- Status: Granted
- Kind: B2
- Application number: 13/146,531
- Filed: 2010-01-25
- Published: 2012-01-19
- Granted: 2014-07-22
- Earliest claimed: 2009-01-28
- Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Applicants: Steven A. Rosenberg; Richard A. Morgan; Timothy L. Frankel; Peter Peng
- Inventors: Steven A. Rosenberg; Richard A. Morgan; Timothy L. Frankel; Peter Peng
- Web page: https://patentgrep.com/patent/US8785601B2

## CPC

- C07K 14/70503: {Immunoglobulin superfamily}
- A61P 35/00: Antineoplastic agents
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides T cell receptors (TCRs) having antigenic specificity for a cancer antigen, e.g., tyrosinase. Also provided are related polypeptides, proteins, nucleic acids, recombinant expression vectors, isolated host cells, populations of cells, and pharmaceutical compositions. The invention further provides a method of detecting the presence of cancer in a host and a method of treating or preventing cancer in a host using the inventive TCRs or related materials.

## Claims

### Claim 1

A T cell receptor (TCR) comprising the amino acid sequences of SEQ ID NO: 1-6 and 18-19.

### Claim 2 (depends on 1)

The TCR of claim 1, comprising the amino acid sequences of SEQ ID NO: 20 and 21.

### Claim 3

An isolated or purified TCR comprising the amino acid sequences of SEQ ID NO: 7 and 8 and SEQ ID No: 18 and 19.

### Claim 4 (depends on 1)

An isolated or purified polypeptide comprising a functional portion of the TCR of claim 1 comprising the amino acid sequences of SEQ ID NO: 20 and 21.

### Claim 5 (depends on 1)

An isolated or purified polypeptide comprising a functional portion of the TCR of claim 1, wherein the functional portion comprises the amino acid sequences of SEQ ID NO: 7, 8, 18, and 19.

### Claim 6

An isolated or purified protein, comprising a first polypeptide chain comprising the amino acid sequences of SEQ ID NO: 7 and 18, and a second polypeptide chain comprising the amino acid sequences of SEQ ID NO: 8 and 19.

### Claim 7 (depends on 6)

The isolated or purified protein of claim 6, comprising a polypeptide chain comprising an α chain comprising SEQ ID NO: 20 and a β chain comprising SEQ ID NO: 21.

### Claim 8 (depends on 1)

A composition comprising the TCR of claim 1 and a pharmaceutically acceptable carrier.

### Claim 9 (depends on 2)

A composition comprising the TCR of claim 2 and a pharmaceutically acceptable carrier.

### Claim 10 (depends on 3)

A composition comprising the TCR of claim 3 and a pharmaceutically acceptable carrier.

### Claim 11 (depends on 4)

A composition comprising the polypeptide of claim 4 and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 5)

A composition comprising the polypeptide of claim 5 and a pharmaceutically acceptable carrier.

### Claim 13 (depends on 6)

A composition comprising the protein of claim 6 and a pharmaceutically acceptable carrier.

### Claim 14 (depends on 7)

A composition comprising the protein of claim 7 and a pharmaceutically acceptable carrier.